MAP 2018 – Molecular Analysis for Personalised Therapy is a one-of-a-kind meeting designed by a faculty of highly influential key opinion leaders. A truly unique programme will feature speakers with the highest publication track record in the field.
MAP 2018 is the place to network with the leading academic representatives working in personalised medicine for cancer patients.
MAP 2018 is a joint initiative of Cancer Research UK, UNICANCER and ESMO and aims to provide oncologists with expert guidance on interpreting genomic alterations to design tailored treatment programmes for their patients.
The meeting is highly recommended for medical oncologists, young professionals, academics, regulators, industry R&D representatives and investigators and all those interested in discussing the clinical interpretation of molecular tests with a view to providing effective cancer treatment.
Fabrice André, Villejuif, France
John Haanen, Amsterdam, The Netherlands
Charlie Swanton, London, United Kingdom
European Society for Medical Oncology
CANCER RESEARCH UK
Affiliate Scientific Partner
Fabrice André, Institute Gustave Roussy, Villejuif, France
Jean-Charles Soria, MedImmune Gaithersburg, Maryland, United States
Charles Swanton, The Francis Crick Institute, London, United Kingdom
28 June 2018: MAP Congress 2018: Interpreting Molecular Alterations for Clinical Practice
10 September 2018: Following the tumour DNA trail to crack the secrets of personalised medicine